Sino Biopharmaceutical Limited (SBHMY)
USD 9.48
(-7.96%)
USD 9.48
(-7.96%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 25.43 Billion CNY | -2.63% |
| 2022 | 26.12 Billion CNY | 14.49% |
| 2021 | 22.81 Billion CNY | -7.97% |
| 2020 | 24.79 Billion CNY | 37.61% |
| 2019 | 18.01 Billion CNY | 47.29% |
| 2018 | 12.23 Billion CNY | 46.93% |
| 2017 | 8.32 Billion CNY | 8.08% |
| 2016 | 7.7 Billion CNY | 52.29% |
| 2015 | 5.05 Billion CNY | 18.31% |
| 2014 | 4.27 Billion CNY | 99.36% |
| 2013 | 2.14 Billion CNY | 31.15% |
| 2012 | 1.63 Billion CNY | 32.98% |
| 2011 | 1.22 Billion CNY | 9.35% |
| 2010 | 1.12 Billion CNY | 72.95% |
| 2009 | 650.1 Million CNY | 19.97% |
| 2008 | 541.9 Million CNY | 54.11% |
| 2007 | 351.63 Million CNY | 91.0% |
| 2006 | 184.1 Million CNY | 7.21% |
| 2005 | 171.73 Million CNY | -34.93% |
| 2004 | 263.92 Million CNY | 3.28% |
| 2003 | 255.54 Million CNY | 40.44% |
| 2002 | 181.95 Million CNY | 86.77% |
| 2001 | 97.42 Million CNY | -36.31% |
| 2000 | 152.96 Million CNY | 8.34% |
| 1999 | 141.18 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 24.58 Billion CNY | 0.0% |
| 2024 Q1 | 24.58 Billion CNY | -3.35% |
| 2023 Q3 | 25.43 Billion CNY | -12.84% |
| 2023 Q4 | 25.43 Billion CNY | 0.0% |
| 2023 Q2 | 29.18 Billion CNY | 0.0% |
| 2023 FY | 25.43 Billion CNY | -2.63% |
| 2023 Q1 | 29.18 Billion CNY | 11.72% |
| 2022 Q3 | 26.12 Billion CNY | -0.26% |
| 2022 FY | 26.12 Billion CNY | 14.49% |
| 2022 Q4 | 26.12 Billion CNY | 0.0% |
| 2022 Q1 | 26.18 Billion CNY | 14.8% |
| 2022 Q2 | 26.18 Billion CNY | 0.0% |
| 2021 Q4 | 22.81 Billion CNY | 0.0% |
| 2021 FY | 22.81 Billion CNY | -7.97% |
| 2021 Q1 | 24.3 Billion CNY | -1.98% |
| 2021 Q3 | 22.81 Billion CNY | -9.1% |
| 2021 Q2 | 25.09 Billion CNY | 3.28% |
| 2020 Q3 | 25.74 Billion CNY | -4.12% |
| 2020 FY | 24.79 Billion CNY | 37.61% |
| 2020 Q1 | 25.55 Billion CNY | 41.87% |
| 2020 Q2 | 26.84 Billion CNY | 5.04% |
| 2020 Q4 | 24.79 Billion CNY | -3.69% |
| 2019 Q1 | 13.47 Billion CNY | 10.18% |
| 2019 Q2 | 14.65 Billion CNY | 8.79% |
| 2019 Q4 | 18.01 Billion CNY | 23.05% |
| 2019 FY | 18.01 Billion CNY | 47.29% |
| 2019 Q3 | 14.63 Billion CNY | -0.14% |
| 2018 Q4 | 12.23 Billion CNY | 2.91% |
| 2018 Q3 | 11.88 Billion CNY | 11.19% |
| 2018 Q2 | 10.68 Billion CNY | 7.83% |
| 2018 Q1 | 9.91 Billion CNY | 19.08% |
| 2018 FY | 12.23 Billion CNY | 46.93% |
| 2017 Q2 | 8.69 Billion CNY | -0.34% |
| 2017 Q4 | 8.32 Billion CNY | -4.21% |
| 2017 FY | 8.32 Billion CNY | 8.08% |
| 2017 Q1 | 8.72 Billion CNY | 13.28% |
| 2017 Q3 | 8.68 Billion CNY | -0.05% |
| 2016 Q1 | 5.98 Billion CNY | 18.26% |
| 2016 FY | 7.7 Billion CNY | 52.29% |
| 2016 Q4 | 7.7 Billion CNY | -1.91% |
| 2016 Q3 | 7.85 Billion CNY | 19.67% |
| 2016 Q2 | 6.56 Billion CNY | 9.7% |
| 2015 FY | 5.05 Billion CNY | 18.31% |
| 2015 Q1 | 4.98 Billion CNY | 16.54% |
| 2015 Q2 | 6 Billion CNY | 20.6% |
| 2015 Q3 | 6.2 Billion CNY | 3.32% |
| 2015 Q4 | 5.05 Billion CNY | -18.53% |
| 2014 Q3 | 4.29 Billion CNY | -4.49% |
| 2014 FY | 4.27 Billion CNY | 99.36% |
| 2014 Q4 | 4.27 Billion CNY | -0.57% |
| 2014 Q1 | 2.89 Billion CNY | 35.1% |
| 2014 Q2 | 4.5 Billion CNY | 55.4% |
| 2013 FY | 2.14 Billion CNY | 31.15% |
| 2013 Q3 | 2.43 Billion CNY | 2.3% |
| 2013 Q2 | 2.37 Billion CNY | 19.71% |
| 2013 Q1 | 1.98 Billion CNY | 21.37% |
| 2013 Q4 | 2.14 Billion CNY | -11.77% |
| 2012 FY | 1.63 Billion CNY | 32.98% |
| 2012 Q4 | 1.63 Billion CNY | -21.31% |
| 2012 Q3 | 2.07 Billion CNY | 10.89% |
| 2012 Q2 | 1.87 Billion CNY | 0.0% |
| 2011 Q3 | 1.67 Billion CNY | -4.6% |
| 2011 Q2 | 1.75 Billion CNY | 41.49% |
| 2011 Q1 | 1.23 Billion CNY | 0.0% |
| 2011 FY | 1.22 Billion CNY | 9.35% |
| 2011 Q4 | 1.22 Billion CNY | -26.45% |
| 2010 Q2 | 1 Billion CNY | 0.0% |
| 2010 FY | 1.12 Billion CNY | 72.95% |
| 2009 FY | 650.1 Million CNY | 19.97% |
| 2009 Q4 | 650.1 Million CNY | 0.0% |
| 2008 FY | 541.9 Million CNY | 54.11% |
| 2007 FY | 351.63 Million CNY | 91.0% |
| 2006 FY | 184.1 Million CNY | 7.21% |
| 2005 FY | 171.73 Million CNY | -34.93% |
| 2004 FY | 263.92 Million CNY | 3.28% |
| 2003 FY | 255.54 Million CNY | 40.44% |
| 2002 FY | 181.95 Million CNY | 86.77% |
| 2001 FY | 97.42 Million CNY | -36.31% |
| 2000 FY | 152.96 Million CNY | 8.34% |
| 1999 FY | 141.18 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Bioxytran, Inc. | 3.24 Million USD | -782631.682% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -47615.723% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -6033295.799% |
| SQZ Biotechnologies Company | 50.03 Million USD | -50730.085% |
| Intellipharmaceutics International Inc. | 12 Million USD | -211702.477% |
| Evofem Biosciences, Inc. | 72.47 Million USD | -34996.612% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -42999.68% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -660301.607% |
| Marizyme, Inc. | 26.67 Million USD | -95248.409% |
| Genus plc | 485 Million USD | -5144.302% |
| Pharming Group N.V. | 244.07 Million USD | -10321.008% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -1265234.381% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -1010692.949% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -669238.579% |
| ContraFect Corporation | 32.53 Million USD | -78086.548% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -664403.789% |
| IMV Inc. | 37.93 Million USD | -66952.445% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -215848.76% |
| ONE Bio Corp. | 27.49 Million USD | -92404.516% |
| RVL Pharmaceuticals plc | 77.41 Million USD | -32754.368% |
| Mesoblast Limited | 188.44 Million USD | -13397.262% |
| MultiCell Technologies, Inc. | 1617.67 USD | -1572314772.625% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | -30568.434% |
| Genscript Biotech Corporation | 1.32 Billion USD | -1818.35% |
| Neon Bloom, Inc. | 1.22 Million USD | -2074161.649% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -494161.427% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -265343.619% |
| Biomind Labs Inc. | 1.49 Million USD | -1697128.235% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -281190.868% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -138107.316% |
| Skye Bioscience, Inc. | 14.07 Million USD | -180645.112% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -1773772.502% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -435233.149% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -17899802.178% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -1283641.145% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -268599.327% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -12646763.502% |
| Accustem Sciences Inc. | 1.07 Million USD | -2356640.815% |
| EV Biologics, Inc. | 2.11 Million USD | -1202454.905% |
| Q BioMed Inc. | 8.13 Million USD | -312638.925% |
| GB Sciences, Inc. | 5.41 Million USD | -469389.587% |
| Alpha Cognition Inc. | 7.16 Million USD | -354898.86% |
| CSL Limited | 18.62 Billion USD | -36.592% |
| Agentix Corp. | 2.51 Million USD | -1013017.259% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | -21323.847% |
| Enzolytics Inc. | 365.26 Million USD | -6863.324% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Resverlogix Corp. | 67.39 Million USD | -37639.43% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -3032437.926% |
| MetaStat, Inc. | - USD | -Infinity% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -442567.218% |
| argenx SE | 444.95 Million USD | -5616.33% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | -33849.367% |
| HST Global, Inc. | 593.59 Thousand USD | -4284799.923% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -1483847.841% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -2019833.878% |
| Halberd Corporation | 728.71 Thousand USD | -3490253.072% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -102683.635% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -693862.562% |
| Zenith Capital Corp. | 27.56 Thousand USD | -92258835.761% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -213582.687% |
| GeneThera, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -681013.599% |
| AVAX Technologies, Inc. | 3.99 Million USD | -636767.552% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -3735739.573% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -937887.956% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -10657532.388% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| NovAccess Global Inc. | 7.86 Million USD | -323468.67% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -38002658.147% |
| Capstone Therapeutics Corp. | 50.26 Million USD | -50502.551% |
| Kadimastem Ltd | 3.5 Million USD | -725601.318% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 15.9 Million USD | -159820.77% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -5473306.657% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -92716212.47% |
| LadRx Corporation | 2.2 Million USD | -1155752.868% |
| Cell Source, Inc. | 15.8 Million USD | -160811.787% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -56906258.511% |
| Regen BioPharma, Inc. | 5.45 Million USD | -465943.525% |
| Regen BioPharma, Inc. | 5.45 Million USD | -465943.525% |
| Affymax, Inc. | 8.87 Million USD | -286619.265% |
| Mobile Lads Corp. | 1.31 Million USD | -1936323.608% |
| Itoco Inc. | 1.65 Million USD | -1538468.83% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -1239678.706% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -420380.509% |
| International Stem Cell Corporation | 5.27 Million USD | -481894.808% |
| CytoDyn Inc. | 127.89 Million USD | -19787.458% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -60850317.474% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -1623702.316% |
| Qrons Inc. | 1.48 Million USD | -1708413.73% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -230177.958% |
| SYBLEU INC | 681.41 Thousand USD | -3732565.212% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -3144689.155% |
| Rebus Holdings, Inc. | 5.24 Million USD | -485113.01% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -416734.841% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -4064217.707% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -550781.035% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -61942.311% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -114136.991% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -1255702.768% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -464209.346% |
| Neutra Corp. | 973.52 Thousand USD | -2612545.951% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -87561.093% |
| PureTech Health plc | 125.58 Million USD | -20153.431% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -676876.837% |
| IXICO plc | 1.9 Million USD | -1338371.456% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -123797.248% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -24516.61% |
| CSL Limited | 18.62 Billion USD | -36.592% |
| Cellectis S.A. | 249.36 Million USD | -10099.674% |